Jim Simons Aspira Women'S Health Inc. Transaction History

Renaissance Technologies LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.32 - $0.58 $544 - $985	-1,700 Reduced 6.67%	23,800 $9,000
Q4 2022 Feb 13, 2023	SELL	$0.3 - $0.41 $782 - $1,068	-2,607 Reduced 9.28%	25,500 $8,000
Q3 2022 Nov 14, 2022	SELL	$0.38 - $1.07 $207,137 - $583,255	-545,099 Reduced 95.1%	28,107 $10,000
Q2 2022 Aug 12, 2022	SELL	$0.4 - $1.09 $223,838 - $609,958	-559,595 Reduced 49.4%	573,206 $337,000
Q1 2022 May 13, 2022	BUY	$0.88 - $1.81 $155,826 - $320,505	177,075 Added 18.53%	1,132,801 $1.18 Million
Q4 2021 Feb 11, 2022	BUY	$1.63 - $3.43 $598,089 - $1.26 Million	366,926 Added 62.32%	955,726 $1.69 Million
Q3 2021 Nov 12, 2021	BUY	$3.19 - $5.48 $1.54 Million - $2.65 Million	483,113 Added 457.12%	588,800 $1.91 Million
Q2 2021 Aug 13, 2021	BUY	$4.78 - $6.84 $505,183 - $722,899	105,687 New	105,687 $594,000
Q1 2021 May 13, 2021	SELL	$5.9 - $9.13 $103,657 - $160,404	-17,569 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$3.0 - $6.71 $52,707 - $117,887	17,569 New	17,569 $118,000

431K

Ticker AWH
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 124,296,000
Market Cap $123M
Description
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gyneco...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.